J. McClean

795 total citations
23 papers, 512 citations indexed

About

J. McClean is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, J. McClean has authored 23 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 11 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in J. McClean's work include Lung Cancer Treatments and Mutations (8 papers), Nausea and vomiting management (5 papers) and Pathogenesis and Treatment of Hiccups (5 papers). J. McClean is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Nausea and vomiting management (5 papers) and Pathogenesis and Treatment of Hiccups (5 papers). J. McClean collaborates with scholars based in United States, India and Ireland. J. McClean's co-authors include Lawrence H. Einhorn, Cynthia S. Johnson, Patrick J. Loehrer, Steven D. Passik, Jake Vinson, Rudolph M. Navari, L H Einhorn, Kenneth Pennington, Nasser H. Hanna and Mary Lou Mayer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

J. McClean

22 papers receiving 496 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. McClean United States	10	265	173	150	116	111	23	512
Tania Perrone Italy	12	164 0.6×	109 0.6×	90 0.6×	42 0.4×	27 0.2×	23	410
Massimiliano Salati Italy	12	200 0.8×	394 2.3×	118 0.8×	197 1.7×	186 1.7×	25	743
Beat Thuerlimann Switzerland	14	94 0.4×	257 1.5×	33 0.2×	46 0.4×	113 1.0×	23	502
Breton Roussel United States	8	74 0.3×	82 0.5×	81 0.5×	62 0.5×	93 0.8×	21	327
Dimitrios Delakas Greece	13	212 0.8×	69 0.4×	37 0.2×	159 1.4×	287 2.6×	24	559
A. Norton United Kingdom	8	61 0.2×	173 1.0×	257 1.7×	63 0.5×	290 2.6×	13	628
Masahiro Shimokawa Japan	11	79 0.3×	102 0.6×	82 0.5×	158 1.4×	97 0.9×	25	454
Der Sheng Sun South Korea	15	70 0.3×	226 1.3×	62 0.4×	228 2.0×	120 1.1×	40	570
An Hang Yang Taiwan	12	141 0.5×	55 0.3×	41 0.3×	145 1.3×	100 0.9×	15	470
Bas W.G. van Rhijn Netherlands	12	610 2.3×	123 0.7×	120 0.8×	243 2.1×	164 1.5×	36	821

Countries citing papers authored by J. McClean

Since Specialization

Citations

This map shows the geographic impact of J. McClean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. McClean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. McClean more than expected).

Fields of papers citing papers by J. McClean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. McClean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. McClean. The network helps show where J. McClean may publish in the future.

Co-authorship network of co-authors of J. McClean

This figure shows the co-authorship network connecting the top 25 collaborators of J. McClean. A scholar is included among the top collaborators of J. McClean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. McClean. J. McClean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fisher, William B., Rafat Ansari, Erwin Robin, et al.. (2012). Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe. Journal of Thoracic Oncology. 7(4). 760–763. 22 indexed citations

Jalal, Shadia I., Tareq Al Baghdadi, Sumeet Bhatia, et al.. (2012). Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non–Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77. Clinical Lung Cancer. 14(3). 224–229. 8 indexed citations

Schmitt, John, et al.. (2011). Sunitinib plus paclitaxel in patients with advanced esophageal cancer: A phase II study from the Hoosier Oncology Group.. Journal of Clinical Oncology. 29(15_suppl). e14661–e14661. 5 indexed citations

Fisher, William B., Daniel Bruetman, J. McClean, et al.. (2008). Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group. Journal of Thoracic Oncology. 3(4). 374–379. 19 indexed citations

Matei, Daniela, Robert E. Emerson, Jeanne M. Schilder, et al.. (2008). Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum‐resistant ovarian cancer and primary peritoneal carcinomatosis. Cancer. 113(4). 723–732. 62 indexed citations

Navari, Rudolph M., Lawrence H. Einhorn, Patrick J. Loehrer, et al.. (2007). A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Supportive Care in Cancer. 15(11). 1285–1285. 115 indexed citations

Matei, Daniela, Robert E. Emerson, Jeanne M. Schilder, et al.. (2006). Clinical activity of imatinib mesylate in combination with docetaxel in patients with advanced, platinum-resistant ovarian cancer—Hoosier Oncology Group GYN03–62. Journal of Clinical Oncology. 24(18_suppl). 5091–5091. 4 indexed citations

Navari, Rudolph M., Lawrence H. Einhorn, Patrick J. Loehrer, et al.. (2006). A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV). Journal of Clinical Oncology. 24(18_suppl). 8608–8608. 4 indexed citations

Ganjoo, Kristen N., Michael J. Robertson, William B. Fisher, et al.. (2005). A Phase II Study of Single Agent Gemcitabine in Relapsed or Refractory Follicular or Small Lymphocytic Non-Hodgkin Lymphomas. American Journal of Clinical Oncology. 28(2). 169–172. 6 indexed citations

10.

Navari, Rudolph M., Lawrence H. Einhorn, Steven D. Passik, et al.. (2005). A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study. Supportive Care in Cancer. 13(7). 529–534. 112 indexed citations

11.

Shaheen, Montaser, et al.. (2004). Phase II Study of Ifosfamide Plus Daily Oral Etoposide in Previously Treated Ovarian Cancer. American Journal of Clinical Oncology. 27(3). 229–231. 4 indexed citations

12.

Navari, Rudolph M., Lawrence Einhorn, Patrick J. Loehrer, et al.. (2004). A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV). Journal of Clinical Oncology. 22(14_suppl). 8046–8046. 1 indexed citations

13.

Miller, KD, Pierluigi Porcu, Rafat Ansari, et al.. (2002). Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. Annals of Oncology. 13(10). 1612–1615. 6 indexed citations

14.

Zoň, Robin, J. McClean, Rafat Ansari, et al.. (2001). Altretamine for the Treatment of Metastatic Renal Cell Carcinoma – A Hoosier Oncology Group Trial. Investigational New Drugs. 19(3). 229–231. 1 indexed citations

15.

Sandler, Alan, Scott Saxman, Douglas K. Heilman, et al.. (1998). Ifosfamide in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology. 21(2). 195–197. 9 indexed citations

16.

Mantravadi, R., A. Sandler, Joseph F. Montebello, et al.. (1998). A phase III hoosier oncology group study of thoracic radiotherapy (TRT) plus cisplatin (P) and vinblastin (V) with or without hydroxgurea (HX) for locally unresectable non small cell lung cancer (NSCLC). International Journal of Radiation Oncology*Biology*Physics. 42(1). 168–168. 2 indexed citations

17.

Miller, Kathy D., Patrick J. Loehrer, René Gonin, et al.. (1996). A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. Investigational New Drugs. 14(2). 207–212. 8 indexed citations

18.

McClean, J. & Alan D. Wilson. (1994). Glass-Ionomer Cements. The Journal of the American Dental Association. 125(8). 1045–1048. 1 indexed citations

19.

Saxman, Scott, Rafat Ansari, R. E. Drasga, et al.. (1992). Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer: A hoosier oncology group study. Cancer. 70(10). 2488–2492. 20 indexed citations

20.

Einhorn, L H, Kenneth Pennington, & J. McClean. (1990). Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.. PubMed. 17(1 Suppl 2). 32–5. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact